Mr Phil Willis MP, Chairman of the House of Commons’ Science and Technology Select Committee, who unveiled the plaque said, “It is a huge privilege to officially open the new ‘Minerva’ research facility which offers emerging biotech companies state of the art facilities to bring excellent science to the market. This facility is a superb example of how government funding can stimulate knowledge transfer by sponsoring direct links between academia and industry and stimulating wealth creation in the regions.”
Minerva is the first of three BioDevelopment buildings, offering flexible laboratory and office accommodation, which are anticipated will stimulate and facilitate the knowledge transfer process from research to commercial exploitation on the campus. Dr David Hardman, CEO of BBT said, “This BioDevelopment building is the latest development in our Babraham Research Campus strategy to integrate world class science with innovative bioventures to exploit new technologies relating to human healthcare. This building enables companies to expand into new facilities on flexible terms, a unique proposition in the region. The campus has been home to over 40 of the region’s biotechnology companies since it opened in 1998 and BBT will start a new Bioincubator building in September. The continued success emphasises the role our knowledge-based campus can play in promoting biosciences for regional development.”
Cambridge Biotechnology Ltd, a drug-discovery research company developing novel therapeutics for the treatment of pain, inflammation and obesity, is one of the four companies residing in Minerva. Dr Peter Richardson, Managing Director of CBT said, "Moving to new facilities at Babraham represents a major new phase in the growth of CBT. The new laboratories will provide CBT's drug discovery teams with excellent working conditions and will ensure optimal efficiency and safety for all its research staff. A location on the Babraham Research Campus also benefits from the proximity of a host of innovative biotech companies and prestigious academic groups which provides an optimal environment for a company such as CBT to thrive."
Also in Minerva are NovaThera Ltd, a spin-out from Imperial College London that is pioneering applications of biomaterials and stem cell biology for regenerative medicine and tissue engineering, and Stem Cell Sciences plc, an international company with centres in the United Kingdom, Australia, Japan and the USA. Active in the stem cell research field since 1994, the company is principally focused on expertise to grow, differentiate, select and purify stem cells. Cyclacel, the Dundee-based biopharmaceutical company dedicated to the discovery, development and commercialisation of novel, mechanism-targeted drugs to treat human cancers, moved into Minerva from the Bioincubator facilities earlier this year.
Claire Cockcroft | alfa
Seeing on the Quick: New Insights into Active Vision in the Brain
15.08.2018 | Eberhard Karls Universität Tübingen
New Approach to Treating Chronic Itch
15.08.2018 | Universität Zürich
Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...
Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.
When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...
Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.
Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....
Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.
Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...
Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur
What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...
08.08.2018 | Event News
27.07.2018 | Event News
25.07.2018 | Event News
15.08.2018 | Physics and Astronomy
15.08.2018 | Earth Sciences
15.08.2018 | Physics and Astronomy